Parker Waichman LLP

Vytorin Makers Defend Drug Following Cancer Findings

Vytorin makers Merck and Schering-Plough are preparing to send a letter to thousands of physicians in an attempt to address cancer concerns raised by a recently published study. While the companies acknowledge that Vytorin users enrolled in the SEAS study had higher rates of cancer than those taking placebo, the letter characterized the finding as […]

<"https://www.yourlawyer.com/topics/overview/vytorin">Vytorin makers Merck and Schering-Plough are preparing to send a letter to thousands of physicians in an attempt to address cancer concerns raised by a recently published study. While the companies acknowledge that Vytorin users enrolled in the SEAS study had higher rates of cancer than those taking placebo, the letter characterized the finding as an “anomaly”.

This latest Vytorin study – known as SEAS – was presented Monday in London by its primary researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway. The study, which involved 1873 patients, investigated the effects of Vytorn in patients with aortic stenosis. Aortic stenosis involves partial blockage of the aortic valve in the heart. Left untreated, it can progress to death from heart failure or cardiac arrest. Aortic valve replacement for severe symptoms is the second most frequent type of heart surgery. Apart from surgery, there is no medical therapy known to prevent or heal this condition.

In addition to failing to show that Vytorin did much to help patients with aortic stenosis avoid other heart problems, a safety analysis of SEAS found that Vytorin patients in the study had higher rates of cancer and cancer deaths. In the trial 102 patients taking Vytorin developed cancer, compared with 67 taking the placebo. Of those, 39 people taking Vytorin died from their cancer, compared with 23 taking placebo. Researchers conducting the study said that while those numbers don’t prove a definitive cancer link, they were “statistically significant”, meaning the odds were less than 5 percent that they were the result of chance.

In a letter being sent to doctors, Merck and Schering-Plough state that “the cancer finding in SEAS is likely to be an anomaly that, taken in the light of all the available data, does not support an association with Vytorin”. The companies said they have made the Food & Drug Administration (FDA) aware of the SEAS findings, ” we do not believe that changes in the clinical use of Vytorin are warranted.”

Vytorin has been under fire since January, when Merck and Schering-Plough finally released the long-delayed ENHANCE study. ENHANCE showed Vytorin were ineffective in preventing clogged arteries, and might actually increase plaque in some users. In spite of the findings, Merck and Schering-Plough delayed releasing ENHANCE for more than a year – something critics of the company have likened to fraud.

In March, the full ENHANCE study was vetted during the annual meeting of the American College of Cardiology (ACC). A panel of four doctors concluded that Vytorin should be used only as a last resort, considering that the expensive drug did not provide any added benefits. “Our strongest recommendation is that people need to go back to statins,” said panel member Dr. Harlan Krumhotz.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
They were so helpful and informative throughout the entire process. Especially Jillian. She is amazing!! I definitely recommend
Ari Ari
6 years ago
5 Star Reviews 150
Best support. Best answer. Believe me i am a physical therapist who can meet a lot of lawyers. But, this team especially Jessie, she handles matter with responsibilities for what we are looking for. This is one we are looking for. I deeply touched. Best ever!!
Jiae Kim
4 years ago
5 Star Reviews 150
I would like to thank both Benita Rollis and Shelly Davis for the wonderful job that they have done for me. They made it easy and helped through the hard times. Thank you both. Steven Lubowsky
Steven Lubowsky
a year ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038